Racc1, I agree. If the company had hired a hotshot biotech CEO with tons of experience, the cost would be prohibitively expensive for a small company, and many who are now blasting Gerald would likely be complaining about how many shares or how much cash this hotshot CEO was being paid. And even a hotshot CEO wouldn't be able to advance a product to market any faster than our current CEO has done, given all the testing and validations required. The only way to quicker revenue would be to partner with a big pharma and give away a sizable chunk of our revenue stream and product control to other investors. If we're able to bring our product to market without this kind of arrangement, it will certainly take longer but shareholders will ultimately be rewarded to a greater degree.

That's primarily the problem with this company. Many investors have a short-term focus and want to be instantly wealthy with a BP partnership. The company has a longer-term outlook.